H uman cardiac mesenchymal cells (CMSCs) do not naturally exert contractile functions and do not spontaneously generate cardiomyocytes. Under appropriate conditions, however, they may be genetically redirected to differentiate into cardiomyocytes and contribute in situ to cardiac regeneration. 1 These cells are relatively simple to isolate and expand ex vivo 2 as a population enriched in cells of mesenchymal origin (≥90% CD29-CD90-CD146 positive). 2 For this reason and thanks to their secretory properties, CMSCs have been recently considered of therapeutic interest for cardiac repair. 3, 4 However, little is still known about the effect of the cardiac metabolic microenvironment on the biological properties of cardiac nonmyocyte cell populations. 5 
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Clinical trials for type 1 and 2 diabetes mellitus demonstrated that early glycemic control reduces incidence and progression of diabetic complication. 6 On the other hand, epidemiological and prospective data revealed that in the cardiovascular system diabetes mellitus stressors may persist in spite of glycemic control. 7 Indeed, a prolonged impairment of glucose homeostasis is a condition that often precedes and accompanies obesity, metabolic syndrome, insulin resistance, and type 1 and 2 diabetes mellitus. The permanent or long-term consequence of an early inefficient glucose handling has been defined as hyperglycemic memory, [8] [9] [10] a phenomenon believed of epigenetic origin 11 where specific changes in the histone code and DNA methylation level may provide the mechanistic basis for the perpetuation of an altered metabolic signals. 12, 13 In spite of some advances, how mechanistically epigenetic changes may affect function of CMSCs is still poorly characterized. Recent work, however, provided some evidence that DNA methylation plays an important role in this process. 14, 15 The recent discovery of α-ketoglutaric acid (αKG)-dependent, iron-dependent, and oxygen-dependent TET (ten-eleven translocation protein)-1,-2,-3 proteins shed light on DNA demethylation mechanisms via conversion of 5-methylcytosine (5mC) into its oxidized forms such as 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine. 16 The outcome of this process is active demethylation of targeted DNA regions. Remarkably, once acquired, some of the 5mC iterative modifications, including 5hmC and 5fC, remain stable in the DNA of nonregenerating adult mouse organs including brain and heart. 17, 18 Several epigenetic enzymes contribute to the DNA demethylation process including members of the AID/APOBEC 
Novelty and Significance
What Is Known?
• Stable epigenetic DNA modifications are introduced in living cells and organs.
• Cellular metabolism regulates function of several epigenetic enzymes.
• Metabolic syndrome or diabetes mellitus alters the cellular epigenetic landscape.
• Specific epigenetic modifications are associated to the onset of metabolic memory.
• Cardiac cells of stromal origin are of therapeutic relevance.
What New Information Does This Article Contribute?
• Ex vivo cultured cardiac mesenchymal cells (CMSCs) from diabetic donors accumulate iteratively oxidized forms of methylated DNA.
• This epigenetic alteration is associated with a reduced intracellular synthesis of α-ketoglutarate (αKG) in vitro and in vivo.
• αKG regulates not only TETs (ten-eleven translocation proteins) but also TDG (thymine DNA glycosylase) activity promoting DNA demethylation in cardiac cells.
• A newly identified drug, inhibiting αKG dehydrogenase, rescued intracellular αKG levels leading to DNA demethylation in vitro and in vivo.
Primary goal of this study has been the multi-OMIC characterization of therapeutically relevant CMSCs of stromal origin isolated from diabetic and nondiabetic donors and observed in a controlled ex vivo environment. In this condition, an elevated content of methylated and iteratively oxidized cytosines was detected globally and in the CpG islands of some cell cycle and metabolically relevant genes. Surprisingly, similar findings were observed in the heart of mice exposed to high-fat diet, injected with streptozotocin, or both in combination (streptozotocin/high-fat diet). In this context, αKG was found reduced in diabetic CMSCs and in the heart of high-fat diet and in streptozotocin mice leading to the TET1/TDG complex disassembly and to a significant decrease of TDG activity. This condition was rescued by supplementing diabetic CMSCs with a cell-permeable form of αKG and, in vivo, by the intraperitoneal administration of (S)-2-[(2,6-dichlorobenzoyl) amino]succinic acid (AA6), a novel inhibitor of the αKG dehydrogenase. Both treatments increased the content of αKG that, acting as an allosteric activator of TDG, triggered DNA demethylation in diabetic CMSCs and in the mouse heart and other organs. As a consequence, glucose uptake, insulin response, and cellular function significantly improved.
family and the TDG (thymine DNA glycosylase). 19, 20 In particular, TDG plays a fundamental role, alone or in association with TET1, 21 in the formation of an abasic site that can be reconverted to unmethylated cytosine with the final contribution of the base excision repair machinery. 22 To our knowledge, TDG has never been reported metabolically regulated. The evidence that it may form a complex with TET1, 21 however, opens up to the possibility that specific pathophysiological metabolic environments, such as those in cancer, chronic inflammation, insulin resistance, or diabetes mellitus, may have implications on TET/TDG function and DNA demethylation. 23, 24 In the present work, we took advantage from the possibility to isolate human primary CMSCs from diabetic (D-CMSC) and nondiabetic (ND-CMSC) donors analyzing them after few rounds of ex vivo expansion. We found that some important epigenetic alterations resided in D-CMSCs compared with ND-CMSCs cultured in the same condition. Information is reported here about how epigenetic changes were determined in D-CMSCs, with special attention paid to the mechanism of iteratively oxidized DNA cytosine accumulation, 25 and how to pharmacologically rescue this alteration.
Methods
All relevant data are available from the authors. The RNA sequencing data sets have been made publicly available at GEO and can be accessed at https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE106181. DNA sequencing data sets are available from the corresponding author on request. All supporting data methods are available as Online Data Supplement.
Results

Accumulation of Methylated Cytosines and Their Iteratively Oxidized Modifications Occurs in Human CMSCs From Diabetic Donors, in the Heart of Mice With Impaired Glucose Homeostasis and in Human Endothelial Cells Exposed to High Glucose
Accumulation of 5mC, and that of its oxidized products, 5hmC and 5fC, occurred in the DNA of human CMSCs obtained from diabetic donors compared with nondiabetic donors (Online Table I ; Figure 1A through 1C) . Notably, peripheral blood mononuclear cells, isolated from the same diabetic donors did not show a similar pattern for cytosine modifications (Online Figure IA through IC) . In diabetic peripheral blood mononuclear cells, in fact, only 5fC significantly accumulated (Online Figure IC) , suggesting this modification as one of the oxidized DNA cytosine modifications most sensitive to the Figure 1 . Global 5-cytosine modification increase in human cardiac mesenchymal cells (CMSCs) from diabetic donors. A, Quantification of 5-methylcytosine (5mC; n=8), (B) 5-hydroxymethylcytosine (5hmC; n=14), and (C) 5-formylcytosine (5fC; n=12) in CMSCs isolated from nondiabetic (ND-; black circles) and diabetic (D-; white squares) donors. D, Left, Representative in-cell western analysis of ND-and D-CMSCs probed with anti-5hmC and 5fC antibodies. Signals normalized to DNA content according DRAQ5 staining. Right, Densitometry of 3 independent experiments. E, Representative confocal microscopy images depicting the intracellular content of 5hmC and 5fC in ND-and D-CMSCs. Cells probed by anti-5hmC antibody (green; upper) and anti-5fC antibody (green; lower) and counterstained with vimentin (purple). Scale bar, 10 μm. Error bars indicate SE. *P<0.05; **P<0.01; ***P<0.001. Data analyzed by Kolmogorov-Smirnov test. metabolic environment. These observations, about the accretion of 5hmC and 5fC in D-CMSCs, were confirmed at single cell level by in-cell Western and confocal analyses ( Figure 1D and 1E). Further, exploring 5mC and 5hmC accumulation in the mitochondrial DNA of a subset of randomly chosen human ND-and D-CMSCs, we found a pronounced accumulation of Remarkably, modifications similar to those present in D-CMSCs were observed in the whole heart and in the brain of different animal models of impaired glucose handling such as in high-fat diet (HFD)-fed mice, mice injected with highdose streptozotocin (STZ), or treated with low-dose STZ plus HFD 26 (Online Figures IIA through IIF and XIA through XID). Confocal analysis, performed at the latest experimental time points, confirmed the presence of 5hmC also in cardiomyocytes of HFD, STZ, and STZ+HFD mice ( Figure 6K ; Online Figure XIA and XIB). Because of their intrinsically stable inability to handle blood glucose (Online Figure IIE) , mice made hyperglycemic by STZ injection were analyzed in greater detail. In them, cardiac DNA hypermethylation, characterized by accumulation of 5mC, 5hmC, and 5fC, became detectable as early as 1 month after blood glucose rose >200 mg/dL. Interestingly, the level of those cytosine modifications remained relatively stable during a time course from 5 to 25 weeks (Online Figure IIG) . Accordingly, we found that 
An Integrated OMIC Approach Reveals Altered Functional Pathways in Human CMSCs of Diabetic Origin
The reduced representation of bisulfite genomic sequencing validated the presence of a significant accumulation of 5mC and 5hmC in D-CMSCs. Among the genomic features, modified CpG sequences were abundant in the promoter regions (Figure 2A and 2B). In particular, the coincident presence of 5mC and 5hmC, interested repressed genes involved in transcriptional processes, proliferation, metabolism, and regulation of glucose import (Online Table II) , as indicated by gene ontology analysis (Online Figure IIIA) .
RNA sequencing, performed in phenotypically consistent but independent subsets of ND-and D-CMSCs, revealed a large number of differentially regulated genes that clearly separated the 2 populations ( Figure 2C ; Online Table III) . Interestingly, the transcripts upregulated in D-CMSCs were involved in matrix synthesis, cell adhesion, signaling, motility, and apoptosis, consistent with cell activation and death programs ( Figure 2D , red bars). The downregulated transcripts ( Figure 2D , blue bars), instead, belonged to transcriptional regulation, proliferation, and DNA metabolism, indicative of a potentially causal link with the original pathophysiological environment. Similarly, KEGG pathway analysis indicated extracellular matrix synthesis, cell adhesion, apoptosis, and cytoskeletal remodeling as the most represented pathways (Online Figure To further investigate this aspect, we evaluated αKG impact on the expression of molecules involved in the mitochondrial fission/fusion conversion and the rate of oxygen consumption. Mfn1 (mitofusin1) was reduced in D-CMSCs; conversely, the Drp1 (dynamin-like 1 protein), abundant during mitochondrial fission, was significantly increased (Online Figure VJ) . This phenotype was rescued by αKG treatment. Consistently, rate of oxygen consumption returned to control value in the presence of αKG (Online Figure  VK) . However, exogenous αKG supplementation was of little or no effect on ND-CMSCs in terms of proliferation (Online 
TET1/TDG Association Is Compromised in Human CMSCs From Type 2 Diabetes Mellitus Patients
To further explore TET/TDG activity in CMSCs, total TET and TDG activities were measured in a series of in vitro assays. Online Figure VIIA and VIIB show that both enzymes were hypofunctioning in D-CMSCs. This finding was paralleled by the evidence that TET1 and TDG did not associate well in D-CMSCs (Online Figure VIIC) . Intriguingly, experiments with oxalomalic acid, an IDH inhibitor (Online Figure VIID) , reproduced the phenotype of D-CMSCs in ND-CMSCs. Specifically, the inhibition of IDH reduced αKG and the TET/TDG association (Online Figure VIIE and VIIF) . These results suggest that αKG may be important for TET/ TDG complex formation and function. Indeed, they resulted affected in an αKG-reduced intracellular environment like the one of D-CMSCs or of HFD-fed mice heart (see below).
To explore αKG effect, confocal analysis was performed in ND-and D-CMSCs ( Figure 3A) . As expected, TDG (green) has been found localized to the nucleus. Surprisingly, TET1 (red) localization was nuclear in ND-CMSCs and cytoplasmic in D-CMSCs. This alteration was rescued by adding an αKG extracellular source ( Figure 3A) . Interestingly, an extranuclear distribution of TET1 was observed in ND-CMSCs treated with okadaic acid, an inhibitor of cellular phosphatases of the PP2a family (Online Figure VIIG) . These results were consistent with our prior work, providing evidence that in human endothelial cells, the class II HDAC (histone deacetylases) nuclear localization was sensitive to the action of PP2a (protein phosphatase 2) phosphatase family.
αKG Triggers TET1/TDG Complex Formation and TDG Activation
Among the multiple roles assigned to αKG, the effect on DNA demethylation was further investigated in our system. Figure 3B and 3C show that the addition of an exogenous source of αKG to D-CMSCs reduced the presence of 5hmC and 5fC in their genomic DNA and that of 5hmC in the mitochondrial one (Online Figure VIIH) . This observation suggested that the metabolite triggered an active DNA demethylation process in these metabolically compromised cells.
The experimental evidence that αKG-induced global DNA demethylation including a significant reduction in 5fC prompted us to consider that TDG itself could be sensitive to the intracellular level of this metabolite. No information, however, is currently available on the impact that αKG might have on TET/TDG complex formation 21 or TDG function per se. Figure 3D shows that TET1/TDG association is significantly improved in D-CMSCs by αKG, an evidence paralleled by the intranuclear relocalization of TET1 ( Figure 3A, lower) . Unexpectedly, Figure 3E shows that an exogenous source of αKG significantly increased TDG activity in cellular extracts obtained from D-CMSCs, thus suggesting for a direct effect of this metabolite on TDG.
αKG Is an Allosteric Cofactor of TDG and Regulates Its Activity
Although no prior knowledge is available about αKG as a potential cofactor/modulator of TDG, we found an αKG-binding consensus motif, RxxxxxR, 30 at position 275 to 281 of the human TDG protein ( Figure 4A ) similar to that of the RNA demethylase ALKBH5. 30, 31 In this motif, the Arginine at position 275 (Arg275) was the most interspecies conserved residue ( Figure 4A ). Thus, we speculated that αKG might interact directly with TDG to regulate its function. To explore this possibility, we took advantage from molecular dynamics (MD) simulation. αKG was found to rapidly (≈10 ns) approach the TDG protein surface stably binding to the enzyme ( Figure 4B) . Notably, the metabolite did not access to the catalytic core but remained anchored to the positively charged region at its entrance resulting in a local variation of the electrostatic surface potential ( Figure 4C ; Online Table VA) . A persistent interaction with Arg275 (R275) was established, which was identified as the key determinant for the recognition and interaction between αKG and TDG ( Figure 4D ). The MD analysis of a TDG R275→Ala (A) mutant (TDG R275A ) further substantiated this model by showing a complete loss of affinity between αKG and TDG R275A (Online Figure VIIIA) . Moreover, αKG was unable to recognize a preformed TDG/ DNA-5fC complex (Online Figure VIIIB) . In this context, some H-bond interactions between αKG and TDG resulted in the most populated cluster of MD conformations (37.5% of MD time). Specifically, H-bond interactions were established with Gly156 (also bridged by a water molecule), Asn157, and Ser273 (Online Figure VIIIC) . In MD simulation, the binding of αKG to TDG induced a slight conformational change in the loops Pro270-Arg281, Gly149-His158, and Asn191-Gly199, possibly allowing the catalytic active site to accommodate a αKG molecule (Online Figure VIIID and VIIIE) . Further, to identify the potential relevance of αKG/TDG interaction, additional MD simulations were performed on (1) TDG and DNA bearing 5fC in the TDG catalytic site (DNA-5fC), the structure was adapted from the protein crystallographic data (ID 3UO7) 22 and (2) the ternary complex TDG/αKG/DNA5fC. These analyses demonstrated that TDG/αKG preformed complex binds DNA-5fC in a conformationally stable structure (Online Figure VIIIF, left; Online Table VA) . Specifically, αKG, in the most populated cluster of MD conformations (58.5% of MD time), occupied the TDG catalytic pocket without hampering or competing with the binding to 5fC (Online Figure VIIIF, right) . Theoretical affinity calculations (Online Table VB) suggest that, in the presence of αKG, TDG has a reduced affinity for its target DNA. Taken together, MD simulations indicated that αKG does not hamper the excision repair mechanism of TDG; rather it might exert an allosteric function with potential consequences for the catalytic activity turnover of the enzyme.
To validate the MD prediction that αKG modulated TDG affinity for its DNA targets, experiments were performed assessing the effect of exogenous αKG on the efficiency of TDG-dependent base excision process and abasic sites binding. Here, evidence is provided that in the presence of αKG, a purified mrTDG (murine recombinant TDG protein) recognized more efficiently a DNA oligo bearing a G/T mismatch ( Figure 5A ). In parallel, the G/T excision activity of mrTDG was increased about 3-fold by αKG ( Figure 5B) . Similarly, mrTDG protein recognized genomic DNA abasic site reducing accessibility to the fluorescent aldehyde reactive probe ( Figure 5C, black bar) . Interestingly, αKG restored aldehyde reactive probe signal to control level ( Figure 5C , gray bar) and increased the ability of mrTDG to remove 5fC from a synthetic substrate ( Figure 5D ). The further evidence that αKG protected the mrTDG protein against degradation in a series of thermal shift experiments 32 supported our findings ( Figure 5E ), about a direct and functionally relevant interaction between αKG and TDG. Conversely, a cell extract thermal shift assay, 33 comparing wild-type and TDG R275A as well as TET1 and the TET1 mutant for the αKG-responsive residue R2043→A (TET1 R2043A ), 34 showed a complete loss of protection by αKG for both mutated proteins ( Figure 5F ). In this context, the R275A mutation of TDG abrogated αKG effect, supporting the hypothesis that R275 regulates the interaction of TDG with αKG in the context of a metabolitedependent allosteric activation of the enzyme ( Figure 5G ). To explore further this evidence, experiments were performed in HEK293T cells in which the endogenous TDG was knocked out by CRISPR/Cas9 technology and reconstituted by transfection of wild-type or mutant TDG. Figure 5H shows a representative Western blotting analysis of 2 independent TDG KO clones and their reconstitution by myc-tagged wild-type or mutant TDG. Figure 5I shows αKG effect treatment on wildtype endogenous TDG before and after reconstitution in the 2 independent CRISPR/Cas9 clones. Always, in the presence of αKG, wild-type TDG activity increased twice above the basal level ( Figure 5I , grey columns). The TDG R275A mutant, however, abrogated this effect ( Figure 5I ). Similarly, TDG abrogation prevented αKG from prompting genomic DNA demethylation, and specifically, the removal of 5fC which accumulated in the absence of TDG or in cells reconstituted with the TDG R275A mutant ( Figure 5J ). Mechanistically, Figure 5K provides the evidence that TDG R275A variant does not complex with TET1, suggesting that αKG association with TDG may be important for TET/TDG complex formation and demethylation function. Similar results were obtained by siRNA knockdown of TET and TDG in ND-CMSCs and D-CMSCs. Online Figure IXA through IXE shows that in siRNA, TET/TDG CMSCs 5fC significantly accumulated above control level, and αKG response was abrogated. Further, TDG knockout in H9C2 cells differentiated into cardiomyocytes 35, 36 (Online Figure IXF) reproduced the deficient phenotype described above indicating that the TDG is active as a DNA demethylation enzymes also in cells of cardiomyogenic lineage (Online Figure IXG and IXH) .
A Synthetic αKG Dehydrogenase Inhibitor Rescues Intracellular αKG Levels and Activates TET/TDG Complex Formation and Function Reducing Global DNA Methylation
Hereafter, we investigated whether our findings could be translated into a preclinical setting. Intriguingly, in diabetic patients, αKG plasma concentration has been reported to be similar to that of nondiabetic subjects. 37 We extended and confirmed this early observation by using plasma samples collected from donors and from HFD mice (Online Figure XA and XB) . In light of this evidence, we reasoned that the intracellular αKG level might be the limiting factor. Considering, in fact, that unmodified αKG is hydrophilic and cannot efficiently cross the plasma membrane, 28 it is conceivable that the extracellular part of this metabolite might be ineffective to rescue the alteration in DNA methylation detected in models of impaired glucose homeostasis. To circumvent this problem, we screened a library of small molecules 38 for potential regulators of DNA demethylation and identified (S)-2-[(2,6-dichlorobenzoyl)amino] succinic acid (AA6; Online Figure XC) as a direct interactor of αKG dehydrogenase complex (OGDH), determined by cell extract thermal shift assay 33 ( Figure 6A ). AA6 acts as an enzyme inhibitor ( Figure 6B ) able to increase αKG intracellular levels ( Figure 6C ). In the presence of AA6, TDG activity significantly increased ( Figure 6D ), whereas the global DNA content of 5hmC and 5fC was reduced ( Figure 6E and 6F) at an extent similar to that observed after direct administration of the cell-permeable αKG analog ( Figure 3B and 3C) . Notably, a similar effect was obtained in D-CMSCs by siRNA knockdown of OGDH expression as shown in Online Figure  XD through XF. Specifically, the reduction in OGDH expression and function determined an intracellular accumulation of αKG (Online Figure XE) with a small but significant effect on the total DNA content of 5fC (Online Figure XF) .
In vivo, in HFD mice fed for 5 weeks and treated daily with AA6 (25 mg/kg) for additional 5 weeks, AA6 increased cardiac αKG levels ( Figure 6G ), an effect paralleled by the reassembly of TET1/TDG complex ( Figure 6H ) and TDG activity gain ( Figure 6I ). In parallel, 5mC, 5hmC, and 5fC accumulation was normalized ( Figure 6J ). This observation was further supported by confocal analysis showing positivity for 5hmC in the nuclei of some cardiomyocytes of HFD, STZ, and STZ/HFD mice ( Figure 6K ; Online Figure XIA and XIB). The number of these nuclei significantly decreased in HFD animals treated with AA6 ( Figure 6K) . A similar effect was detected in the genomic DNA obtained from the brain of the same animals where 5hmC and 5fC significantly accumulated and diminished after AA6 treatment (Online Figure XIC  and XID) . Of note, no significant accumulation of modified cytosines was observed in liver with or without AA6, possibly reflecting organ-specific differences in metabolism, pharmacokinetics, or cellular turnover (Online Figure XIC and  XID) . 17, 18 Interestingly, during the 5 weeks of AA6 treatment, no adverse reactions to the drug or sudden death episodes occurred. Further, no signs of proliferation or cardiotoxicity were detected (Online Figure XIE and XIF).
AA6 Rescues Glucose Uptake in D-CMSCs and Insulin Response in HFD Mice Promoting Irs1 and Irs2 Expression
During the progress of this work, bioinformatic analysis revealed that in D-CMSCs, compared with ND-CMSCs, Irs1 and Irs2 gene loci were enriched in methylated cytosines at their 5′-region (Online Figure IIIC) . In addition, a recent work showed that Irs1 and Irs2 are downregulated in the heart in consequence of an altered metabolic state, a condition typical of HFD mice. 39 We reasoned that these 2 genes could be important targets in the glucose response regulation in D-CMSCs and decided to challenge the system with AA6. Remarkably, Irs1 and Irs2 loci were methylated and hydroxymethylated in D-CMSCs (Online Figure IIIC) . However, AA6 reduced the level of 5mC and 5hmC in the genomic region encompassing Irs1 and Irs2 genes (Online Figure XIIA and XIIB) leading to reactivation of gene expression (Online Figure XIIC) . This effect was paralleled by an increase of intracellular glucose content in D-CMSCs (Online Figure XIID) and a reassessment of the mitochondrial rate of oxygen consumption at control level, whereas no significant effect was observed in ND-CMSCs (Online Figure XIIE) .
Whishing to explore AA6 effect in an in vivo context, a series of experiments were performed in mice exposed to HFD in the presence or absence of the drug. Figure 7A shows the results of RNA sequencing related to the whole heart of Figure 7 Continued. Representative WB analysis of 3 independent whole heart tissue lysates from Ctr, HFD±AA6 probed with carboxymethyl lysine (CML) antibody. GADPH used as loading control. Right, Densitometry. E, Animal body weight during standard diet (Ctr) and HFD feeding. Black arrow indicates AA6 starting treatment after 6 wk. Numeric data provided as online. F, Blood glucose quantification in Ctr (white squares, n=12; 8.19±0.39), HFD (black triangles, n=12; 13.25±0.63), and HFD+AA6 (orange circles, n=12; 9.91±0.64) mice. G, Oral glucose tolerance test (OGTT) in Ctr, HFD, and HFD+AA6 mice. Numeric data provided as online. H, Serum insulin level of mice fed with standard diet (Ctr, white squares, n=7; 6.19±1.28), HFD (black triangles, n=10; 21.06±2.82), or HFD+AA6 (orange circles, n=7; 8.67±1.81). I, Heatmap showing the 50 most differentially regulated genes in tibialis muscle of Ctr, HFD, and HFD+AA6 by total RNA sequencing. Red and blue represent over-and underexpressed genes, respectively. Yellow square: differentially regulated genes in HFD (n=3). Orange squares: genes rescued by HFD+AA6 (n=3). J, GO analysis of HFD differentially regulated genes in tibialis muscle of Ctr and HFD (blue bar graph). K, GO analysis of AA6-rescued transcripts in tibialis muscle between HFD-fed mice and HFD+AA6 (orange bar graph). L, Left, Representative WB analysis of 3 independent tissue extracts from heart (upper) and tibialis muscle (lower) of Ctr, HFD, and HFD+AA6 mice probed with insulin response substrate 1 and 2 genes (Irs1 and Irs2) antibodies. α-tubulin was used as loading control. Right, Densitometry. Error bars indicate SE. *P<0.05; **P<0.01; ***P<0.001. Data analyzed by KolmogorovSmirnov test (D, L), 1-way ANOVA with Bonferroni post hoc test (F, H), and 2-way ANOVA (E, G).
HFD±AA6 mice compared with control condition. Data indicate that HFD significantly changed the pattern of cardiac transcripts which was rescued in HFD animals injected with AA6 (Online Table VI; Figure 7A ). In this context, gene ontology analysis revealed that some transcripts associated with important cardiac functions including contractility, metabolism, and homeostasis were compromised ( Figure 7B) . Notably, treatment with AA6 restored these pathways at control levels with a predominant transcriptional effect on the expression of genes encoding for components of the sarcomeres or proteins involved in calcium handling and cardiac differentiation ( Figure 7C ). Interestingly, this pattern was at least in part similar to that observed in the transcriptomic analysis of ND-and D-CMSCs ( Figure 2D ). To explore further the basis of AA6 beneficial effect, we measured the cardiac accumulation of advanced glycation end products, the body weight gain and blood glycemia basal level in HFD mice with or without AA6. In all cases, we observed a positive effect. Specifically, advanced glycation end product accumulation was reduced in HFD animals treated with AA6 ( Figure 7D ) as well as the body weight gain and the total blood glycemia that showed a significant amelioration in the presence of the drug ( Figure 7E and 7F). Further, the effect of AA6 was paralleled by a normalization of the glucose uptake curve ( Figure 7G ) and the insulin levels ( Figure 7H ), suggesting for a positive influence on the systemic insulin response. To explore this possibility, RNA sequencing was performed on total RNA extracted from mouse skeletal muscle (Online Table VII; Figure 7I ). Similarly to the heart, AA6 treatment had an effect on gene expression with a partial rescue at control level ( Figure 7I ). Gene ontology analysis indicated that signaling pathways associated with insulin response, metabolism, and differentiation processes were, in fact, depressed in HFD-fed mice ( Figure 7J ). However, this effect was reverted by AA6 treatment ( Figure 7K ). Importantly, as seen in D-CMSCs, AA6 promoted Irs1 and Irs2 expression in the skeletal muscle and in the heart of HFD+AA6-treated animals ( Figure 7L) .
Additional experiments, performed in mice made hyperglycemic by STZ and evaluated after 3 months from injection, showed that AA6 failed to restore normal blood glucose (Online Figure XIIIA) . Nevertheless, the DNA demethylation determined by AA6 treatment occurred in the heart in spite the presence of high blood glucose (Online Figure XIIIB through  XIIID) . This effect was paralleled by an increase of total cardiac αKG level similarly to that seen in HFD mice treated with the drug (Online Figure XIIIE; Figure 6G , respectively).
Discussion
Mesenchymal cells are abundant in the cardiac stroma and may either represent a source of regenerating material in the occasion of heart damage and a potential problem in several pathophysiological conditions leading to fibrosis and heart failure. 5, 40, 41 In spite of its relevance, little is known about the effect of chronic diseases or metabolic derangements on cardiac stroma and its cellular components. Our prior work reported that CMSCs isolated from patients with clinical history of diabetes mellitus and cultured ex vivo demonstrated a variety of epigenetic alterations including the accumulation of specific histone code modifications and DNA cytosine methylation at cell cycle gene promoters.
14 These observations were compatible with the presence of a hyperglycemic/ epigenetic memory phenotype in cells originating from diabetic donors. Recently, we observed that a similar epigenetic landscape was reproduced in the heart of mice after that hyperglycemia was caused by STZ injection (see this work and reference 35 ). This finding reinforced the concept that, in the absence of other pathophysiological conditions, a prolonged period of uncontrolled hyperglycemia 9, 10, 15, 42, 43 could be sufficient to trigger for the introduction of stable and transmissible epigenetic modifications at cellular and organismal level. 17, 18 Here, we investigated this hypothesis in the attempt to provide mechanistic information about those signals contributing to the accumulation of epigenetic modifications in human CMSCs. Specifically, attention has been paid to those changes having a direct impact on DNA structure and function such as cytosine methylation and its iterative oxidized modifications that have been recently implicated in epigenetic memory transmission. 44 DNA methylation is emerging as an important epigenetic modification introduced and regulated by a complex network of enzymes whose activity depends on cofactors, such as S-adenosylmethionine or αKG, synthesized during metabolic processes. 45 Specifically, αKG can regulate DNA and histone methylation level acting on TET1, TET2, TET3 and histone lysine demethylases 2 to 7 (KDM2/7), all members of the so-called 2-oxoglutarate-dependent dioxygenase family. 46 In particular, TET proteins are responsible of the DNA demethylation process introducing iterative oxidized variants of 5mC like 5hmC, 5fC, and 5-carboxylcytosine that are preparatory for the final removal of the modified cytosine and the reintroduction of the original unmethylated residue. 20 Indeed, variation in the αKG availability or synthesis may affect DNA methylation, gene expression, and cellular differentiation. 47, 48 The recent identification of different iterative cytosine modifications immediately opened the question about their functional role in the regulation of gene expression and their relevance in pathophysiological conditions such as cancer, cardiovascular diseases, or diabetes mellitus. 49, 50 Despite a body of literature indicates that an altered DNA methylation pattern exists in all these situations, the role of the iteratively oxidized cytosine modifications remains unclear. 51 In cancer, the presence of mutations in TET2 gene suggests that its product may be crucial in the process of cellular transformation which may be, at least in part, associated with a deregulated rate of 5mC→5hmC conversion and that of other subsequent modifications. [52] [53] [54] Altogether, the evidence of a deregulation of DNA demethylation through mutations in TET enzymes and in the IDH genes, the enzymes deputed to the synthesis of their cofactor αKG, may provide a new conceptual framework for a better understanding of the interplay among metabolism, DNA methylation, and the onset of specific diseases. 55 Once acquired, in fact, DNA methylation modifications, such as 5hmC and 5fC, are thought to be stable possibly contributing to epigenetic memory establishment, 42, 45, 47, 48 a condition still mechanistically poorly understood and largely underestimated at clinical level.
The DNA demethylation process not only requires TET proteins but, to complete the demethylation cycle, other enzymes including TDG must contribute. TDG, in fact, works with TET1 to facilitate 5fC and 5-carboxylcytosine removal from genomic DNA 21, 22 generating abasic sites prone to the reconstitution of unmethylated G:C sequences by members of the AID/APOBEC and base excision repair machinery. 56 With a similar mechanism, TDG also removes thymine, uracil, and 5-bromouracil from mispairings with guanine and plays a central role in cellular defense against genetic mutation caused by spontaneous deamination of 5mC or cytosine. Of note, when TDG is hypofunctional, a relative genome enrichment in 5fC has been observed. 57 Although associated to a metabolite-dependent protein such as TET1, 21 TDG is not known to require metabolites and metals to exert its function. In light of this evidence, the finding described in this article about the TDG association with αKG, which acts as an enzyme allosteric activator, is novel and may contribute to understand how iteratively oxidized cytosines accumulate in cells from the heart of diabetic donors or in organs of animals with impaired glucose handling. In these conditions, TET1/TDG complex is reduced and TDG function compromised. This is a scenario compatible with a defective removal step leading to upstream modified cytosines accumulation. In addition, prediction analysis suggested that in the presence of αKG, the energy of the TDG/DNA/5fC complex increases (Online Table VA ). This prediction, the mutation analysis, and the functional evidence of a higher efficiency in mismatched thymine and 5fC removal further support the role of αKG in TDG regulation. Of note, TDG has an intrinsically elevated affinity for the abasic sites that it creates. 58, 59 This association may slow down TDG catalytic turnover requiring post-translational modifications (eg, ubiquitination) and the contribution of other DNA repair enzymes to facilitate TDG release from its target. 58, 59 On the contrary, the allosteric effect of αKG may improve TDG detachment from apyrimidinic sites as suggested by the abasic site measurement. Hence, we speculate here that, although αKG may not be necessary for TDG basal activity, it may be important for its optimal functional turnover. 60 Our observation may, in fact, represent a case of assisted allosteric activation similar to that reported for the epigenetic enzyme Sirtuin 1 that increases its activity in the presence of synthetic ligands binding the molecule to a single amino acid outside the catalytic site. 61 Noteworthy, during the progress of our work, we identified a new small molecule inhibitor of OGDH, AA6, that acting along the αKG pathway, increased the intracellular αKG, TDG activity, and DNA demethylation in vitro and in vivo. Similarly, OGDH siRNA knockdown largely reproduced the effect of AA6 in CMSCs further supporting the specificity of the new molecule and suggesting a role for OGDH in the control of DNA methylation/demethylation cycle. Indeed, in the presence of AA6, the genomic content of methylated and oxidized cytosines was significantly reduced with evident reactivation signs of the insulin response pathway in D-CMSCs and HFD mice possibly via Irs1 and Irs2 reexpression. In parallel, a beneficial effect has been observed on blood glucose and insulin level, body weight gain and glucose response curve.
Although it remains unclear whether this metabolic amelioration has been achieved exclusively through OGDH inhibition and αKG intracellular accumulation or whether AA6 may have additional effects, based on our findings, we may speculate that a dysregulation of IDH/αKG/OGDH metabolic axis may contribute to the onset of insulin resistance or other metabolic dysfunctions associated to an altered glucose homeostasis. This line of thinking is further reinforced by the evidence that in mice with prolonged hyperglycemia, evaluated after 3 months from STZ injection, AA6 determined cardiac DNA demethylation in the absence of blood glucose normalization. Although more experiments are necessary to fully understand AA6 properties, it is conceivable that it might be the increase in αKG level to determine the beneficial action of this OGDH inhibitor.
Yu et al 62 reported recently that oxidative stress associated to diabetes mellitus in mice may introduce nitrated residues into OGDH protein with potential consequences on the enzyme function. Our observations, in fact, indicate that the metabolic impairment, associated with the exposure to elevated glucose levels, could lead to variations in the intracellular level of key metabolites, including αKG, 63 that in turn could be the primum movens underlying the epigenetic DNA modifications possibly associated with an altered glucose homeostasis.
9,10 αKG response abrogation in the presence of the TDG mutant R275A, TET/TDG complex dissociation determined by the αKG synthesis inhibitor oxalomalic acid, and methylated DNA accumulation seen in the heart of HFD mice and in cellular models, where TET/TDG complex was genetically targeted, are in favor of an important role of αKG contributing to DNA maintenance in our experimental systems.
In conclusion, as depicted in Online Figure XIV , this study suggests that pathophysiological conditions associated with impaired glucose homeostasis, such as diabetes mellitus, may trigger signals in the heart and other organs leading to DNA demethylation machinery alterations as consequence of reduced intracellular αKG content, impaired TDG activity and 5mC, 5hmC, and 5fC accumulation. These alterations are well detectable ex vivo in human CMSCs obtained from diabetic donors, and, in our opinion, their damaging effect should be taken into consideration in the context of potential therapeutic applications. In light of this evidence, the new compound AA6 may represent a prototypic metabolic enhancer of DNA demethylation and a new tool to explore the mechanism leading to the incorporation of stable DNA cytosine modifications in cells and tissues. Further experiments are required to elucidate whether αKG level regulation via a calibrated OGDH functional control may represent a new direction for the development of epimetabolic drugs aimed at preventing/reducing consequences of an altered glucose handling. Indeed, the metabolic modulators of DNA demethylation may open novel avenues to the prevention or treatment of the genomic consequences associated with chronic diseases including the functional rescue of therapeutically relevant cardiac cells. 4 
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